Home Health GSK’s injectable HIV drug reveals promise over day by day tablets – ET HealthWorld | Pharma

GSK’s injectable HIV drug reveals promise over day by day tablets – ET HealthWorld | Pharma

0
GSK’s injectable HIV drug reveals promise over day by day tablets – ET HealthWorld | Pharma

[ad_1]

London: British drugmaker GSK mentioned on Wednesday its long-acting injectable HIV remedy confirmed promise in retaining the viral load suppressed in comparison with day by day oral remedy, particularly in people dealing with challenges with tablet consumption.

The interim evaluation of a late-stage trial on the remedy generally known as Cabenuva demonstrated superior efficacy in sustaining viral load suppression in comparison with day by day oral remedy in people with a historical past of adherence challenges to oral antiretroviral remedy, which is used to suppress and mitigate the development of the illness.

The shortage of constant adherence is a typical cause why some folks residing with HIV battle to maintain the virus in examine, GSK mentioned.

The drug falls beneath GSK’s ViiV Healthcare enterprise, during which Pfizer and Shionogi maintain small stakes.

Sturdy gross sales of medicines for HIV, the virus that causes AIDS, have been one of many drivers behind the corporate’s efficiency final yr, producing 6.44 billion kilos ($8.13 billion) in annual gross sales. It’s a key component of CEO Emma Walmsley’s push to boost investor confidence within the energy of GSK’s drug improvement pipeline.

Cabenuva gross sales greater than doubled to 708 million kilos final yr.

  • Printed On Feb 21, 2024 at 02:28 PM IST

Be a part of the group of 2M+ business professionals

Subscribe to our e-newsletter to get newest insights & evaluation.

Obtain ETHealthworld App

  • Get Realtime updates
  • Save your favorite articles


Scan to obtain App


[ad_2]

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here